R
Ravinder Nath Maini
Researcher at University of Oxford
Publications - 117
Citations - 15494
Ravinder Nath Maini is an academic researcher from University of Oxford. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 51, co-authored 117 publications receiving 15224 citations.
Papers
More filters
Journal ArticleDOI
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Peter E. Lipsky,D. van der Heijde,E W St Clair,Daniel E. Furst,F. C. Breedveld,J. R. Kalden,Josef S. Smolen,M Weisman,Paul Emery,Marc Feldmann,Gregory Harriman,Ravinder Nath Maini +11 more
TL;DR: In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
Journal ArticleDOI
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
M J Elliott,Ravinder Nath Maini,Marc Feldmann,Joachim R. Kalden,C Antoni,Josef S. Smolen,B Leeb,F. C. Breedveld,J D Macfarlane,H Bijl +9 more
TL;DR: The results provide the first good evidence that specific cytokine blockade can be effective in human inflammatory disease and define a new direction for the treatment of rheumatoid arthritis.
Journal ArticleDOI
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
M J Elliott,Ravinder Nath Maini,M Feldmann,A Long-Fox,Peter Charles,Peter D. Katsikis,Fionula M. Brennan,J Walker,H Bijl,John Ghrayeb +9 more
TL;DR: Preliminary results support the hypothesis that TNF alpha is an important regulator in RA, and suggest that it may be a useful new therapeutic target in this disease.
Journal ArticleDOI
Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
M J Elliott,Ravinder Nath Maini,Marc Feldmann,A Long-Fox,Peter Charles,H Bijl,James N. Woody +6 more
TL;DR: Repeat treatment with a chimeric monoclonal antibody to TNF alpha (cA2) in patients having disease flares may be useful therapy in the control of acute disease flares in rheumatoid arthritis and treatment programmes including cA2 may be effective in the long-term management of this disease.
Journal ArticleDOI
Localization of Tumor Necrosis Factor α in Synovial Tissues and at the Cartilage–Pannus Junction in Patients With Rheumatoid Arthritis
TL;DR: Using immunoaffinity-purified polyclonal anti-human recombinant tumor necrosis factor α (TNFα) F(ab′)2 fragments and immunohistochemical techniques, the cells that make TNFα were localized in the inflamed synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA).